The Global Health Body Raises Alert Over Severe Lack of Weight-Loss Medications
Under a tenth of patients that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the therapies.
With over a billion people worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that excess weight is a lifelong illness that can be addressed with thorough and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant barriers to universal availability to the treatments that can assist patients in reducing substantial weight, says the body.
Weight-Loss Drug Supply Crisis
Even under the current most optimistic case, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The advice calls on nations and manufacturers to widen access, via approaches including voluntary licensing.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Operate
The injections imitate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people consume fewer calories.
Individuals typically begin shedding pounds after several weeks of commencing the weekly injections.
Research indicates people may see weight return a year later of halting the medication, because their typical food cravings resume.
To be carrying excess weight increases your likelihood for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity affects people in all nations and was linked to 3.7 million deaths worldwide in 2024, per the health agency.